BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 11.30B +11.7% |
| Revenue (ttm) | 3.66B +18.1% |
| Net Income | -19.12M |
| EPS | -0.10 |
| Shares Out | 193.69M |
| PE Ratio | n/a |
| Forward PE | 10.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,658,731 |
| Open | 57.10 |
| Previous Close | 57.13 |
| Day's Range | 56.91 - 58.38 |
| 52-Week Range | 49.26 - 70.98 |
| Beta | 0.23 |
| Analysts | Buy |
| Price Target | 90.78 (+55.63%) |
| Earnings Date | Nov 2, 2026 |
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA... [Read more]
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was $3.22 billion, an increase of 12.87% compared to the previous year's $2.85 billion. Earnings were $348.90 million, a decrease of -18.26%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price target is $90.78, which is an increase of 55.63% from the latest price.
News
BioMarin Pharmaceutical Transcript: Stifel 2026 Healthcare Conference 2026
Q3 revenue grew 32% and topped $1B as metabolic conditions and Amicus assets drove growth; roughly $220M in synergies are targeted for 2028. Pipeline milestones include BMN 440 and BMN 333 data in 2027 and BMN 820 results in 2028.
BioMarin to Participate in Upcoming Investor Conferences
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Cal...
BioMarin price target lowered to $86 from $87 at JPMorgan
JPMorgan lowered the firm’s price target on BioMarin (BMRN) to $86 from $87 and keeps an Overweight rating on the shares.
BioMarin price target lowered to $60 from $62 at RBC Capital
RBC Capital lowered the firm’s price target on BioMarin (BMRN) to $60 from $62 and keeps a Sector Perform rating on the shares after its in-line Q3 results. The firm…
BioMarin price target lowered to $89 from $94 at Wedbush
Wedbush lowered the firm’s price target on BioMarin (BMRN) to $89 from $94 and keeps an Outperform rating on the shares. The firm says the share price drop on the…
BioMarin price target lowered to $94 from $97 at Oppenheimer
Oppenheimer analyst Leland Gershell lowered the firm’s price target on BioMarin (BMRN) to $94 from $97 and keeps an Outperform rating on the shares following quarterly results. The firm notes…
BioMarin price target lowered to $83 from $86 at BofA
BofA lowered the firm’s price target on BioMarin (BMRN) to $83 from $86 and keeps a Buy rating on the shares. After an “in-line quarter,” the firm notes that the…
BioMarin price target lowered to $66 from $70 at Stifel
Stifel lowered the firm’s price target on BioMarin (BMRN) to $66 from $70 and keeps a Hold rating on the shares.
BioMarin price target lowered to $119 from $122 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on BioMarin (BMRN) to $119 from $122 and keeps an Overweight rating on the shares. BioMarin delivered its first quarter…
BioMarin Pharmaceutical Earnings Call Transcript: Q3 2026
Q3 revenue rose 32% to a record above $1B, with broad portfolio growth. FY guidance was reduced for order timing and geopolitical disruption, while acquisition costs weigh on EPS; pipeline expansion and launches remain key growth drivers.
BioMarin Pharmaceutical Earnings release: Q3 2026
BioMarin Pharmaceutical released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
BioMarin Pharmaceutical Slides: Q3 2026
BioMarin Pharmaceutical has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
BioMarin Pharmaceutical Quarterly report: Q3 2026
BioMarin Pharmaceutical has published its Q3 2026 quarterly earnings report on November 2, 2026.
BioMarin reports Q3 non-GAAP EPS 23c vs. 12c last year
Reports Q3 revenue $1.025B, consensus $1.02B. “BioMarin (BMRN) delivered a strong quarter, with revenue growth of 32%, driven by a more diversified portfolio following the acquisition of Amicus Therap...
BioMarin Reports Third Quarter 2026 Financial and Operating Results
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Gui...
BioMarin signs worldwide license agreement for enzyme replacement therapy
BioMarin (BMRN) has entered into an exclusive worldwide license agreement with GC Biopharma and Hanmi Pharm to develop and commercialize HM15421/GC1134A, an investigational long-acting enzyme replacem...
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront ...
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a confe...
3 Healthcare Stocks with Strong Buy Ratings and Double-Digit Upside
BioMarin Pharmaceutical ($BMRN), Boston Scientific ($BSX), and Ionis Pharmaceuticals ($IONS) are three healthcare stocks with Strong Buy ratings and double-digit upside, according to TipRanks. Leading...
BioMarin price target lowered to $122 from $124 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on BioMarin (BMRN) to $122 from $124 and keeps an Overweight rating on the shares.
BioMarin price target raised to $87 from $86 at JPMorgan
JPMorgan raised the firm’s price target on BioMarin (BMRN) to $87 from $86 and keeps an Overweight rating on the shares.
BioMarin assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of BioMarin (BMRN) with a Buy rating and $88 price target The firm views the company as a turnaround story. Management changes that took…
BioMarin price target raised to $114 from $111 at Barclays
Barclays raised the firm’s price target on BioMarin (BMRN) to $114 from $111 and keeps an Overweight rating on the shares as part of a Q3 earnings preview. BioMarin “sounds…
BioMarin to present ‘encouraging’ results from studies of voxzogo at ASBMR
BioMarin (BMRN) Pharmaceutical announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting in Boston, including results from studies…
BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewsw...